0000899243-23-007265.txt : 20230306 0000899243-23-007265.hdr.sgml : 20230306 20230306211100 ACCESSION NUMBER: 0000899243-23-007265 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230302 FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Provost Jean-Claude CENTRAL INDEX KEY: 0001960060 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 23710872 MAIL ADDRESS: STREET 1: C/O LANTHEUS HOLDINGS, INC. STREET 2: 201 BURLINGTON RD, SOUTH BUILDING CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-02 0 0001521036 Lantheus Holdings, Inc. LNTH 0001960060 Provost Jean-Claude C/O LANTHEUS HOLDINGS, INC. 201 BURLINGTON ROAD, SOUTH BLDG BEDFORD MA 01730 0 1 0 0 Chief Medical Officer Common Stock 2023-03-02 4 A 0 16359 0.00 A 20823 I By Theranostics Consulting SAS Stock Option (right to buy) 73.35 2023-03-02 4 A 0 9535 0.00 A 2033-03-02 Common Stock 9535 9535 I By Theranostics Consulting SAS Consists of 5,453 restricted stock units that vest in equal installments over a three-year period and 10,906 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period. The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The option vests in three equal annual installments beginning on March 2, 2024. /s/ Eric Green, attorney-in-fact 2023-03-06